| CA: Schedule II
DE: Anlage II (Prohibited)
US: Schedule I|
AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012.
It was originally developed by Pfizer in 2009 as an analgesic medication.
AB-PINACA acts as a potent agonist for the CB1 receptor (Ki = 2.87 nM, EC50 = 1.2 nM) and CB2 receptor (Ki = 0.88 nM, EC50 = 2.5 nM) and fully substitutes for Δ9-THC in rat discrimination studies, while being 1.5x more potent.
There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.
AB-PINACA is an Anlage II controlled substance in Germany as of November 2014.
AB-PINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.
It's a Schedule I controlled substance in the USA.
As of October 2015 AB-PINACA is a controlled substance in China.